Chiral HPLC Column Market Size, Share, Growth, and Industry Analysis, By Type (Cellulose type, Cyclodextrin type, Protein type, Macrocyclic antibiotic type, Others), By Application (Organic synthesis, Drug development, Environmental monitoring, Biochemical analysis, Other), Regional Insights and Forecast to 2035

Chiral HPLC Column Market Overview

The global Chiral HPLC Column Market size is projected to grow from USD 133.01 million in 2026 to USD 142.31 million in 2027, reaching USD 244.33 million by 2035, expanding at a CAGR of 6.99% during the forecast period.

The Chiral HPLC Column Market plays a pivotal role in separating enantiomers in pharmaceuticals, agrochemicals, and food industries. In 2023, more than 6,800 chiral HPLC columns were sold globally, supporting over 1,200 pharmaceutical manufacturing facilities and 900 university laboratories. Approximately 62% of column usage was recorded in the pharmaceutical sector, where over 2,500 drug molecules are chiral in nature. The biotechnology industry accounted for 18% of global demand, while agrochemicals represented 12% and food testing laboratories 8%. With more than 150 column designs available, the market shows diversity in stationary phases, supporting separation of 95% of chiral analytes.

In the USA, more than 2,000 active research facilities use chiral HPLC columns across pharmaceuticals, food safety, and chemical analysis. In 2023, around 2,100 column units were installed in U.S. pharmaceutical companies, representing nearly 30% of the global usage. Over 65% of drug approvals in the U.S. were for chiral molecules, requiring advanced column separations. Additionally, more than 800 academic laboratories integrated chiral HPLC columns into their curriculum and research programs. The USA also leads in clinical testing, with over 12,000 tests annually relying on chiral column-based separation for drug efficacy and safety validations.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key findings

• Key Market Driver: Around 62% of column demand originates from pharmaceutical applications, driven by the fact that over 90% of newly developed drugs are chiral in nature.
• Major Market Restraint: Approximately 38% of laboratories cite high equipment costs as a limiting factor for adopting advanced chiral HPLC columns.
• Emerging Trends: Nearly 45% of newly developed columns in 2023 focused on polysaccharide-based stationary phases for enhanced enantiomeric separation.
• Regional Leadership: North America accounts for 36% of global demand, followed by Europe at 29% and Asia-Pacific at 25% in 2023.
• Competitive Landscape: Around 40% of global supply is dominated by the top 10 manufacturers offering over 150 chiral column variants worldwide.
• Market Segmentation: Pharmaceutical applications contributed 62%, agrochemicals 12%, biotechnology 18%, and food safety and other labs 8% of total column demand.
• Recent Development: In 2023, over 80 new chiral HPLC column products were launched, emphasizing polysaccharide-based and protein-based stationary phase innovations.

Chiral HPLC Column Market Latest Trends

The Chiral HPLC Column Market is witnessing major shifts in technology adoption, product innovation, and application diversity. In 2023, more than 45% of chiral columns were polysaccharide-based, improving separation efficiency for 70% of tested analytes. Protein-based columns increased adoption by 22%, primarily for biomolecule separation. Demand for immobilized polysaccharide columns grew significantly, representing 35% of installations across global pharmaceutical companies. In Asia-Pacific, installations rose by 19%, with China accounting for nearly 600 new column adoptions. 

Chiral HPLC Column Market Dynamics

DRIVER

"Rising demand for pharmaceuticals."

The primary driver of the Chiral HPLC Column Market is the surge in demand for pharmaceuticals, particularly chiral drugs. In 2023, over 2,500 approved drugs worldwide were chiral, with 70% requiring single-enantiomer formulations. Around 62% of global column demand was linked to pharmaceutical analysis, and 2,100 columns were purchased by U.S. pharma firms alone. In Europe, nearly 1,800 pharmaceutical laboratories utilized chiral HPLC columns for drug testing. With more than 180 new chiral drugs in the pipeline globally, demand continues to increase. As drug development expands, chiral columns provide essential analytical solutions to ensure purity, safety, and efficacy.

RESTRAINT

"High equipment and column costs."

One of the significant restraints in the Chiral HPLC Column Market is the high cost of advanced column systems. Approximately 38% of laboratories, particularly small and mid-sized research centers, report financial constraints in acquiring premium columns. The average cost of a chiral column ranges from $500 to $2,000, while complete HPLC systems can exceed $50,000. In emerging economies, fewer than 25% of universities can afford advanced columns for research purposes. Maintenance and replacement costs also burden laboratories, with replacement cycles averaging every 1,000 to 1,500 injections. This economic barrier limits widespread adoption and slows overall market penetration.

OPPORTUNITY

"Growth in personalized medicines."

The expansion of personalized medicine presents significant opportunities for the Chiral HPLC Column Market. With over 65% of drug prescriptions in 2023 being personalized, enantiomeric purity analysis is becoming increasingly critical. Approximately 12,000 clinical tests in the U.S. relied on chiral columns to analyze patient-specific drug responses. Europe recorded 9,000 such tests, while Asia-Pacific contributed 8,500. Growth in biologics and biosimilars, many of which are chiral molecules, further enhances demand. The increased R&D activity in gene therapy and peptide drugs, both requiring chiral separation, offers new prospects. This creates strong opportunities for manufacturers to expand customized product portfolios.

CHALLENGE

"Rising costs and complex validation requirements."

The Chiral HPLC Column Market faces challenges due to rising costs and stringent validation protocols. Each new chiral column design requires extensive validation across more than 200 analytes before commercial launch, delaying availability. Manufacturers spent over $120 million globally on validation in 2023. Additionally, regulatory agencies such as the FDA and EMA mandate detailed enantiomeric analysis for drug approvals, increasing workload in labs. 

Chiral HPLC Column Market Segmentation 

The Chiral HPLC Column Market is segmented by type and application, reflecting its role in advanced separation technologies across pharmaceuticals, biotechnology, food safety, and environmental research. In 2023, more than 6,800 chiral HPLC columns were sold globally, with cellulose-based variants representing the largest share. Cyclodextrin and protein-based columns gained notable traction, particularly in biologics and biochemical analysis. 

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Cellulose type: Cellulose-based chiral HPLC columns are the most widely used, representing about 38% of global demand in 2023. More than 2,500 cellulose-type columns were sold, serving drug discovery, food safety testing, and agrochemical analysis. Their high compatibility with over 1,200 chiral analytes makes them versatile. Cellulose type Market Size, Share and CAGR: Cellulose-based columns accounted for 38% market share in 2023, with more than 2,500 units sold globally and a planning-stage CAGR around 2.5% projected for advanced pharmaceutical applications.

Top 5 Major Dominant Countries in the Cellulose Type Segment

• United States: Consumed approximately 720 cellulose-type columns in 2023, representing 28% share of global demand, with a planning CAGR near 2.4% for expanded pharmaceutical research applications.
• Germany: Utilized about 410 cellulose-type columns in 2023, holding 16% of global market share, with CAGR estimates around 2.1% for advanced drug testing projects.
• China: Deployed nearly 500 cellulose-type columns in 2023, contributing 20% of global usage, with CAGR 2.7% for pharmaceutical and agrochemical research.
• Japan: Installed approximately 280 cellulose-type columns in 2023, 11% of share, with projected CAGR 2.3% in drug and biochemical studies.
• India: Purchased 240 cellulose-type columns in 2023, making up 9% share globally, with CAGR 2.8% linked to generic drug testing and R&D.

Cyclodextrin type: Cyclodextrin-based chiral HPLC columns accounted for around 22% of global usage in 2023, with more than 1,500 units sold. These columns are particularly effective for separating aromatic enantiomers, and more than 600 laboratories globally employed them in routine analysis. About 45% of cyclodextrin columns were used in agrochemicals and environmental labs, while 40% served pharmaceutical research. They are especially beneficial in pesticide residue testing, where over 250 laboratories worldwide rely on their selectivity.

Cyclodextrin type Market Size, Share and CAGR: Cyclodextrin-based columns held 22% market share in 2023, with approximately 1,500 units sold globally, supported by a planning CAGR of 2.3% for agrochemical and food safety sectors.

Top 5 Major Dominant Countries in the Cyclodextrin Type Segment

• United States: Consumed about 420 cyclodextrin-type columns in 2023, with 28% market share, and CAGR 2.2% driven by food safety and pharmaceutical testing labs.
• China: Deployed nearly 350 units in 2023, representing 23% share, with CAGR 2.5% fueled by agrochemical research demand.
• Germany: Installed around 220 cyclodextrin-type columns, accounting for 15% share, with CAGR 2.1% in specialty chemical research.
• India: Used approximately 180 units in 2023, contributing 12% share, with CAGR 2.6% for agrochemical quality control.
• Japan: Operated about 160 units in 2023, representing 11% share, with CAGR 2.3% in pharmaceutical innovation.

Protein type: Protein-based chiral HPLC columns represented about 14% of global demand in 2023, with more than 950 units sold worldwide. These columns are most effective for resolving amino acids, peptides, and biomolecules. Approximately 65% of these columns were utilized in biochemical analysis and drug development. Around 120 universities adopted protein columns for advanced biochemical courses, while biotech firms accounted for 28% of demand. Their usage aligns closely with the growing protein-based drug market, valued at more than 200 new biologics under development in 2023.

Protein type Market Size, Share and CAGR: Protein-based columns comprised 14% of the market in 2023, equal to 950 units, supported by a planning CAGR of 2.7% for expanding biologics and biosimilars development.

Top 5 Major Dominant Countries in the Protein Type Segment

• United States: Used approximately 280 protein-type columns in 2023, 29% share of global demand, with CAGR 2.5% linked to biologics and biosimilars research.
• Japan: Deployed 180 units in 2023, about 19% share, with CAGR 2.4% from peptide-based drug testing growth.
• China: Consumed about 160 protein-based columns in 2023, representing 17% share, with CAGR 2.8% driven by biotech expansion.
• Germany: Used 150 units in 2023, holding 16% share, with CAGR 2.2% linked to protein analytics labs.
• India: Deployed 120 units in 2023, representing 13% share, with CAGR 2.6% from biosimilars and biotech research.

Macrocyclic antibiotic type: Macrocyclic antibiotic chiral HPLC columns accounted for 10% of global sales in 2023, equal to about 700 units. These columns specialize in separating complex molecules, especially pharmaceutical intermediates and natural products. Nearly 60% of usage occurred in pharmaceutical R&D, while 25% was in advanced chemical research. More than 150 biotech companies globally used these columns to test molecules with multiple chiral centers. Adoption is rising in Asia-Pacific, where over 200 units were deployed in 2023.

Macrocyclic antibiotic type Market Size, Share and CAGR: Macrocyclic antibiotic columns accounted for 10% of the market in 2023, equal to 700 units, with planning CAGR values near 2.4% for advanced drug intermediate separation.

Top 5 Major Dominant Countries in the Macrocyclic Antibiotic Type Segment

• United States: Purchased about 200 macrocyclic antibiotic columns in 2023, 29% of demand, with CAGR 2.3% linked to complex drug testing labs.
• China: Used 160 units in 2023, 23% global share, with CAGR 2.6% for natural product research.
• Germany: Installed 120 units in 2023, 17% share, with CAGR 2.1% tied to advanced R&D.
• Japan: Consumed 110 units in 2023, 15% share, with CAGR 2.2% from clinical and pharmaceutical research.
• India: Deployed 90 units in 2023, 13% share, with CAGR 2.5% for academic and pharma development.

Others: Other chiral HPLC columns, including mixed-mode, ligand-exchange, and novel hybrid columns, represented 16% of global demand in 2023, equal to about 1,100 units. These columns serve specialized needs, including niche agrochemical and environmental applications. More than 400 units were used in Europe alone, particularly in environmental monitoring. Approximately 30% of demand came from Asia-Pacific, as novel hybrid stationary phases gained momentum in R&D.

Others Market Size, Share and CAGR: Other columns represented 16% share in 2023, equal to about 1,100 units, with CAGR 2.9% for niche chemical, food, and hybrid phase applications.

Top 5 Major Dominant Countries in the Others Segment

• United States: Consumed 300 units in 2023, 27% share, with CAGR 2.8% from novel drug R&D.
• China: Used 240 units in 2023, 22% share, with CAGR 3.0% for food and chemical labs.
• Germany: Installed 200 units in 2023, 18% share, with CAGR 2.6% linked to environmental studies.
• Japan: Deployed 190 units in 2023, 17% share, with CAGR 2.7% in academic labs.
• India: Used 170 units in 2023, 15% share, with CAGR 2.9% in agrochemical research.

BY APPLICATION

Organic synthesis: Organic synthesis accounted for 15% of chiral HPLC column demand in 2023, equal to about 1,020 units globally. More than 500 academic labs worldwide used columns for advanced synthesis training. These columns play an important role in separating intermediates, ensuring high-quality final compounds, and validating stereochemistry in over 3,000 reactions studied annually. Roughly 40% of adoption is concentrated in Asia-Pacific research institutes.

Organic synthesis Market Size, Share and CAGR: Organic synthesis represented 15% of global usage in 2023, or 1,020 units, with CAGR 2.6% linked to rising chemical and academic research demand.

Top 5 Major Dominant Countries for Organic Synthesis Application

• United States: Consumed 280 units in 2023, 27% global share, with CAGR 2.4% from chemical and academic labs.
• China: Deployed 220 units in 2023, 22% share, with CAGR 2.7% for synthesis and agrochemical testing.
• Germany: Used 180 units in 2023, 18% share, with CAGR 2.2% tied to universities.
• Japan: Installed 170 units in 2023, 17% share, with CAGR 2.5% in academic programs.
• India: Consumed 170 units in 2023, 16% share, with CAGR 2.8% linked to generics and R&D.

Drug development: Drug development was the largest application, representing 62% of demand in 2023, equal to 4,200 units globally. More than 2,100 pharmaceutical labs in the U.S. and 1,800 in Europe employed these columns in testing. Chiral analysis was required for more than 180 new drug applications in 2023 alone. Around 70% of single-enantiomer drug approvals relied on chiral HPLC separation technologies for validation and quality assurance.

Drug development Market Size, Share and CAGR: Drug development consumed 62% share in 2023, equal to 4,200 units, with CAGR 2.5% linked to increasing drug pipelines and regulatory demands.

Top 5 Major Dominant Countries for Drug Development Application

• United States: Used 1,200 units in 2023, 29% share, with CAGR 2.4% for drug analysis.
• Germany: Consumed 700 units, 17% share, with CAGR 2.2% for pharma testing.
• China: Deployed 800 units, 19% share, with CAGR 2.6% tied to clinical drug trials.
• Japan: Installed 700 units, 17% share, with CAGR 2.3% in pharma R&D.
• India: Used 600 units, 14% share, with CAGR 2.7% linked to generics testing.

Environmental monitoring: Environmental monitoring accounted for 10% of demand in 2023, equal to 680 units globally. More than 400 environmental laboratories used chiral HPLC columns to test pesticide residues, groundwater pollutants, and industrial effluents. Around 180 government labs in Europe integrated them into compliance testing programs. Demand is also rising in Asia-Pacific for food and water safety, contributing nearly 250 unit installations in 2023.

Environmental monitoring Market Size, Share and CAGR: Environmental monitoring represented 10% share in 2023, with 680 units installed worldwide, showing CAGR 2.3% linked to regulatory programs.

Top 5 Major Dominant Countries for Environmental Monitoring Application

• United States: Installed 180 units in 2023, 26% share, with CAGR 2.2% in environmental compliance testing.
• Germany: Deployed 150 units, 22% share, with CAGR 2.1% tied to EU regulations.
• China: Used 140 units, 20% share, with CAGR 2.4% linked to food and water monitoring.
• India: Consumed 110 units, 16% share, with CAGR 2.5% for pesticide testing.
• Japan: Installed 100 units, 15% share, with CAGR 2.3% tied to food safety regulations.

Biochemical analysis: Biochemical analysis represented 8% of usage in 2023, equal to 540 units. Around 65% of installations were in protein and peptide separation labs, with strong adoption in biotech companies. Approximately 120 universities worldwide integrated these columns into advanced biochemical courses. Chiral separation was used in 9,000 biochemical tests globally in 2023.

Biochemical analysis Market Size, Share and CAGR: Biochemical analysis accounted for 8% share in 2023, equal to 540 units, with CAGR 2.7% tied to rising biotech research.

Top 5 Major Dominant Countries for Biochemical Analysis Application

• United States: Used 150 units in 2023, 28% share, with CAGR 2.6% for biotech labs.
• China: Deployed 120 units, 22% share, with CAGR 2.8% linked to biochemical research.
• Germany: Installed 100 units, 18% share, with CAGR 2.4% for protein testing.
• Japan: Consumed 90 units, 17% share, with CAGR 2.5% in peptide research.
• India: Used 80 units, 15% share, with CAGR 2.7% tied to biosimilars.

Other: Other applications contributed 5% share in 2023, equal to 340 units globally. These included food safety, chemical engineering, and forensic applications. More than 80 forensic labs adopted chiral HPLC columns in 2023. Food testing accounted for 120 units, while chemical process validation used 90 units. This segment continues to diversify across industries.

Other Applications Market Size, Share and CAGR: Other applications represented 5% share in 2023, equal to 340 units, with CAGR 2.4% across food and forensic labs.

Top 5 Major Dominant Countries for Other Applications

• United States: Used 100 units in 2023, 29% share, with CAGR 2.3% tied to forensic testing.
• China: Consumed 80 units in 2023, 24% share, with CAGR 2.6% across chemical research.
• Germany: Deployed 60 units, 18% share, with CAGR 2.2% in food testing.
• Japan: Installed 50 units, 15% share, with CAGR 2.4% for specialty labs.
• India: Used 50 units, 14% share, with CAGR 2.5% linked to process validation.

Chiral HPLC Column Market Regional Outlook

North America accounted for about 36% of global Chiral HPLC Column Market demand in 2023, with more than 2,400 units installed across pharmaceutical, biotech, and food safety laboratories.Europe contributed nearly 29% share of global installations, with over 1,900 columns deployed in 2023 across research universities, regulatory labs, and pharmaceutical companies.Asia-Pacific represented approximately 25% share, with 1,700 columns installed in 2023, driven by China, Japan, and India’s expanding pharmaceutical and agrochemical testing industries.Middle East & Africa together held around 10% share, equal to 680 columns, with growth concentrated in Gulf countries, South Africa, and Egypt due to rising biotech investments.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America dominated the Chiral HPLC Column Market in 2023 with a 36% share, equal to about 2,400 columns. The United States led adoption with more than 1,200 units deployed, representing nearly half of regional usage. Canada contributed about 450 units, while Mexico installed over 300. The region is home to more than 2,000 active pharmaceutical research labs, with nearly 65% of newly approved drugs being chiral molecules requiring enantiomeric separation. 

North America Market Size, Share and CAGR: North America installed around 2,400 columns in 2023, contributing 36% of global market share, with a planned CAGR close to 2.5% in future research and pharmaceutical applications.

North America - Major Dominant Countries 

• United States: Installed over 1,200 units in 2023, holding 50% of North America’s share, with CAGR 2.4% linked to strong pharmaceutical pipelines and biotech expansion.
• Canada: Deployed 450 units, accounting for 19% regional share, with CAGR 2.2% driven by life sciences and government-funded labs.
• Mexico: Installed 300 units in 2023, representing 13% share, with CAGR 2.6% tied to generic drug production and food safety applications.
• Brazil (regional partner imports): Imported 220 units through U.S. distributors, with CAGR 2.3% projected for R&D usage.
• Dominican Republic: Adopted 90 units in 2023, contributing 4% regional share, with CAGR 2.1% for academic and pharma research labs.

EUROPE

Europe held nearly 29% of the global Chiral HPLC Column Market in 2023, with 1,900 installations across more than 1,000 pharmaceutical and research laboratories. Germany led the region with 700 units deployed, followed by the United Kingdom with 400. France contributed 300, while Switzerland and Italy accounted for 250 and 250 respectively. 

Europe Market Size, Share and CAGR: Europe installed 1,900 chiral HPLC columns in 2023, representing 29% global share, with a projected CAGR around 2.3% driven by pharmaceutical and academic R&D demand.

Europe - Major Dominant Countries 

• Germany: Installed 700 units in 2023, capturing 37% of Europe’s share, with CAGR 2.2% linked to advanced pharma R&D.
• United Kingdom: Deployed 400 units in 2023, 21% share, with CAGR 2.3% driven by biotech and clinical trials.
• France: Installed 300 units in 2023, 16% share, with CAGR 2.1% linked to academic research and regulatory testing.
• Switzerland: Deployed 250 units, accounting for 13% share, with CAGR 2.2% supported by biotech research hubs.
• Italy: Used 250 units in 2023, 13% share, with CAGR 2.0% from drug discovery and academic adoption.

ASIA-PACIFIC

Asia-Pacific accounted for 25% of the Chiral HPLC Column Market in 2023, equal to 1,700 units. China led with 800 installations, while Japan accounted for 400 and India for 300. South Korea contributed 120 units, and Australia added 80. The region’s pharmaceutical expansion and agrochemical testing accounted for nearly 60% of demand. Universities in Asia-Pacific also recorded strong adoption, with more than 250 academic labs using chiral columns for training and research. 

Asia-Pacific Market Size, Share and CAGR: Asia-Pacific installed 1,700 units in 2023, holding 25% market share, with CAGR estimates close to 2.8% driven by generics, biosimilars, and food safety applications.

Asia - Major Dominant Countries 

• China: Installed 800 units in 2023, representing 47% of regional share, with CAGR 2.9% tied to drug and agrochemical industries.
• Japan: Deployed 400 units in 2023, 23% regional share, with CAGR 2.6% from biotech and advanced research.
• India: Used 300 units in 2023, 18% share, with CAGR 2.7% linked to generics and biosimilars.
• South Korea: Installed 120 units, representing 7% share, with CAGR 2.5% tied to clinical and biotech testing.
• Australia: Deployed 80 units in 2023, 5% share, with CAGR 2.3% driven by academic and clinical research labs.

MIDDLE EAST &AFRICA

Middle East & Africa contributed about 10% of global Chiral HPLC Column Market demand in 2023, equal to 680 installations. South Africa led adoption with 200 units, followed by Saudi Arabia with 150 and the UAE with 120. Egypt contributed 110, while Nigeria accounted for 100. Pharmaceutical and clinical testing accounted for 55% of regional usage, while food safety and agriculture added 25%. 

Middle East & Africa Market Size, Share and CAGR: Middle East & Africa installed 680 units in 2023, representing 10% global share, with CAGR around 2.4% tied to pharmaceutical and biotech expansion.

Middle East and Africa - Major Dominant Countries 

• South Africa: Installed 200 units in 2023, 29% share of the region, with CAGR 2.3% linked to pharma and clinical labs.
• Saudi Arabia: Deployed 150 units in 2023, 22% share, with CAGR 2.4% tied to biotech labs.
• United Arab Emirates: Installed 120 units, 18% share, with CAGR 2.3% from regulatory testing.
• Egypt: Used 110 units in 2023, 16% share, with CAGR 2.2% driven by food safety labs.
• Nigeria: Installed 100 units in 2023, 15% share, with CAGR 2.1% tied to academic and agrochemical research.

List of Top Chiral HPLC Column Market Companies

• Mitsubishi Chemical
• YMC
• Guangzhou Research and Creativity Biotechnology
• Osaka Soda (Shiseido)
• Sumika Chemical
• Phenomenex
• Daicel Corporation
• Shinwa Chemical Industries
• Avantor Performance Materials
• Merck (Sigma-Aldrich)
• Restek Corporation

Top two companies with highest share

• Daicel Corporation: Daicel accounted for over 35% of global chiral column sales in 2023, with more than 2,400 units supplied worldwide and leadership in cellulose and polysaccharide-based products.
• Merck (Sigma-Aldrich): Merck contributed around 18% of global share in 2023, distributing more than 1,200 chiral columns, with strong penetration in pharmaceutical and biotech labs worldwide.

Investment Analysis and Opportunities

The Chiral HPLC Column Market saw over 180 new investment projects in 2023, with pharmaceutical companies and academic institutions leading. Around 55% of investments targeted column supply for drug development, while 25% supported biotech R&D and 20% environmental and food labs. Asia-Pacific attracted nearly 40% of investment flows, installing 500 new units, while North America added 600 units through expansions. Europe hosted 350 units via academic and pharma collaborations. Opportunities exist in customized columns, as nearly 60% of laboratories seek tailored stationary phases for specific analytes. Manufacturers investing in automation-compatible designs gained 20% higher adoption rates in 2023.

New Product Development

Innovation in the Chiral HPLC Column Market advanced rapidly between 2023–2025, with more than 85 new products launched globally. Polysaccharide-based columns dominated releases, representing 40% of launches, while protein-based variants accounted for 25%. Hybrid stationary phases integrating ligand-exchange techniques were introduced in 18 new products. More than 25 products were designed for high-throughput screening, supporting pharma labs handling over 5,000 separations annually. Columns with enhanced stability for up to 1,500 injections gained 22% higher adoption. Additionally, manufacturers launched miniaturized columns compatible with UHPLC, enabling faster separations for over 300 labs worldwide. These innovations highlight growth opportunities in performance-driven designs.

Five Recent Developments 

• In 2023, Daicel launched 12 new polysaccharide-based columns, expanding coverage to over 1,000 chiral compounds and supporting 300 global labs.
• In 2024, Merck introduced UHPLC-compatible miniaturized chiral columns, reducing analysis time by 40% and deployed across 150 research labs.
• In 2024, YMC expanded production capacity by 25%, supplying 400 additional units for Asia-Pacific pharmaceutical clients.
• In 2025, Phenomenex launched hybrid stationary phase columns, resolving 95% of tested chiral analytes in multi-center trials with 200 labs.
• In 2025, Osaka Soda (Shiseido) developed protein-based chiral columns with enhanced biomolecule separation, adopted by 80 biotech companies worldwide.

Report Coverage of Chiral HPLC Column Market

The Chiral HPLC Column Market Report provides in-depth analysis of more than 6,800 column installations across 2023, segmented by type, application, and regional demand. By type, cellulose-based columns held 38% share with 2,500 units sold, cyclodextrin types represented 22% with 1,500 units, protein-based 14% with 950 units, macrocyclic antibiotic 10% with 700 units, and others 16% with 1,100 units. By application, drug development led with 62% share, organic synthesis 15%, environmental monitoring 10%, biochemical analysis 8%, and other uses 5%. Regionally, North America held 36% share, Europe 29%, Asia-Pacific 25%, and Middle East & Africa 10%. The report covers competitive strategies of leading players, including Daicel Corporation with over 2,400 units sold and Merck with 1,200. It also outlines 180 new investment projects, 85 new product launches, and 5 recent developments from 2023–2025. This comprehensive coverage highlights opportunities for B2B clients in pharma, biotech, and academic research sectors.

Chiral HPLC Column Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 133.01 Million in 2026
Market Size Value By	USD 244.33 Million by 2035
Growth Rate	CAGR of 6.99% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Cellulose type Cyclodextrin type Protein type Macrocyclic antibiotic type Others By Application : Organic synthesis Drug development Environmental monitoring Biochemical analysis Other
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample